Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity (Q40197215)

18 September 2017

title

Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity (English)

1 reference

18 September 2017

10

Yuman Fong

1 reference

18 September 2017

Zhenkun Yu

1

1 reference

18 September 2017

Prasad S Adusumilli

2

1 reference

18 September 2017

David P Eisenberg

3

1 reference

18 September 2017

Elizabeth Darr

4

1 reference

18 September 2017

Ronald A Ghossein

5

1 reference

18 September 2017

Sen Li

6

1 reference

18 September 2017

Shiquan Liu

7

1 reference

18 September 2017

Bhuvanesh Singh

8

1 reference

18 September 2017

Jatin P Shah

9

1 reference

18 September 2017

Richard J Wong

11

1 reference

18 September 2017

publication date

1 January 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

15

1 reference

18 September 2017

issue

1

1 reference

18 September 2017

page(s)

103-113

1 reference

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Effective treatment of pancreatic tumors with two multimutated herpes simplex oncolytic viruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Treatment of aggressive thyroid cancer with an oncolytic herpes virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

The replication-competent oncolytic herpes simplex mutant virus NV1066 is effective in the treatment of esophageal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Effect of inoculation of the viruses of influenza A and herpes simplex on the growth of transplantable tumors in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Herpesvirus entry: an update

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Utilizing tumor hypoxia to enhance oncolytic viral therapy in colorectal metastases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Carcinoembryonic antigen directed herpes viral oncolysis improves selectivity and activity in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Loss of E-cadherin and p27 expression is associated with head and neck squamous tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

E-cadherin is a selective and strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-cadherin with desmosomal components.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Disruption of adherens junctions liberates nectin-1 to serve as receptor for herpes simplex virus and pseudorabies virus entry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300009

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300009

1 reference

18 September 2017

1 reference